CMG Pharmaceutical Co., Ltd. (058820.KQ)
KRW 2975.0
(10.59%)
KRW 2975.0
(10.59%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 19.74 Billion KRW | 314.35% |
| 2022 | 4.76 Billion KRW | 44.32% |
| 2021 | 3.3 Billion KRW | 11.83% |
| 2020 | 2.95 Billion KRW | 0.0% |
| 2019 | - KRW | 0.0% |
| 2018 | - KRW | 0.0% |
| 2017 | - KRW | 0.0% |
| 2016 | - KRW | -100.0% |
| 2015 | 5.33 Million KRW | -99.62% |
| 2014 | 1.41 Billion KRW | 5.49% |
| 2013 | 1.34 Billion KRW | 0.0% |
| 2012 | - KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 25.64 Billion KRW | 79.88% |
| 2024 Q1 | 20.01 Billion KRW | 1.37% |
| 2023 Q3 | 18.67 Billion KRW | -1.29% |
| 2023 Q4 | 19.74 Billion KRW | 5.73% |
| 2023 FY | 26.11 Billion KRW | 289.09% |
| 2023 Q1 | 16.23 Billion KRW | 240.64% |
| 2023 Q2 | 18.91 Billion KRW | 16.55% |
| 2022 Q3 | 3.49 Billion KRW | 3.06% |
| 2022 Q2 | 3.39 Billion KRW | 1.86% |
| 2022 Q1 | 3.33 Billion KRW | 0.9% |
| 2022 Q4 | 4.76 Billion KRW | 36.25% |
| 2022 FY | 6.71 Billion USD | 1216.07% |
| 2021 Q3 | 3.27 Billion KRW | 4.48% |
| 2021 FY | 510.06 Million USD | 3.83% |
| 2021 Q2 | 3.13 Billion KRW | 3.1% |
| 2021 Q4 | 3.3 Billion KRW | 0.82% |
| 2021 Q1 | 3.04 Billion KRW | 2.98% |
| 2020 Q4 | 2.95 Billion KRW | 2.12% |
| 2020 FY | 491.24 Million USD | 262.05% |
| 2020 Q1 | - KRW | 0.0% |
| 2020 Q2 | 2.8 Billion KRW | 0.0% |
| 2020 Q3 | 2.89 Billion KRW | 2.92% |
| 2019 Q2 | - KRW | 0.0% |
| 2019 Q1 | - KRW | 0.0% |
| 2019 Q4 | - KRW | 0.0% |
| 2019 FY | 2.67 Billion USD | 0.0% |
| 2019 Q3 | - KRW | 0.0% |
| 2018 Q3 | - KRW | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | - KRW | 0.0% |
| 2018 Q2 | - KRW | 0.0% |
| 2018 Q1 | - KRW | 0.0% |
| 2017 Q4 | - KRW | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q1 | - KRW | 0.0% |
| 2017 Q2 | - KRW | 0.0% |
| 2017 Q3 | - KRW | 0.0% |
| 2016 Q4 | - KRW | 0.0% |
| 2016 Q2 | 5.44 Million KRW | -1.41% |
| 2016 Q1 | 5.51 Million KRW | 3.52% |
| 2016 Q3 | - KRW | -100.0% |
| 2016 FY | - USD | -100.0% |
| 2015 Q1 | 1.42 Billion KRW | 0.6% |
| 2015 Q4 | 5.33 Million KRW | 0.0% |
| 2015 FY | 3.06 Million USD | 0.0% |
| 2015 Q3 | - KRW | -100.0% |
| 2015 Q2 | 1.43 Billion KRW | 1.13% |
| 2014 Q3 | 1.42 Billion KRW | -2.39% |
| 2014 Q1 | 1.36 Billion KRW | 1.64% |
| 2014 FY | - USD | 0.0% |
| 2014 Q4 | 1.41 Billion KRW | -0.89% |
| 2014 Q2 | 1.46 Billion KRW | 7.28% |
| 2013 FY | - USD | 0.0% |
| 2013 Q1 | 15.93 Billion KRW | 0.0% |
| 2013 Q2 | - KRW | -100.0% |
| 2013 Q3 | 1.37 Billion KRW | 0.0% |
| 2013 Q4 | 1.34 Billion KRW | -2.86% |
| 2012 Q4 | - KRW | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 23.72 Billion KRW | 16.792% |
| Celltrion Pharm, Inc. | 162.52 Billion KRW | 87.852% |
| Huons Global Co., Ltd. | 254.93 Billion KRW | 92.256% |
| DongKook Pharmaceutical Co., Ltd. | 104.74 Billion KRW | 81.151% |
| Enzychem Lifesciences Corporation | 5.65 Billion KRW | -249.007% |
| Humedix Co., Ltd. | 2.7 Billion KRW | -630.761% |
| Boditech Med Inc. | 10.56 Billion KRW | -86.824% |
| EuBiologics Co., Ltd. | 14.77 Billion KRW | -33.592% |
| FutureChem Co.,Ltd | 3.68 Billion KRW | -436.132% |
| Huons Co., Ltd. | 124.61 Billion KRW | 84.156% |
| BNC Korea Co., Ltd. | 737.2 Million KRW | -2578.124% |
| AptaBio Therapeutics Inc. | 13.93 Billion KRW | -41.691% |